Protagonist Therapeutics
PTGX
69 hedge funds and large institutions have $93.6M invested in Protagonist Therapeutics in 2018 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 27 increasing their positions, 22 reducing their positions, and 17 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 22
9.14% more ownership
Funds ownership: 56.56% → 65.7% (+9.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 17
1% less funds holding
Funds holding: 70 → 69 (-1)
9% less capital invested
Capital invested by funds: $103M → $93.6M (-$8.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$11.3M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$7.77M |
| 3 |
Renaissance Technologies
New York
|
+$3.27M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.14M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$9.31M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.84M |
| 3 |
BlackRock
New York
|
-$3.33M |
| 4 |
PI
Pharmstandard International
Luxembourg
|
-$1.78M |
| 5 |
State Street
Boston,
Massachusetts
|
-$1.06M |
PTGX Hedge Fund Activity: Q2 2018 in Review
69 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q2 2018, worth a combined $93.6M — down 8.7% from $103M a quarter earlier.
Fund positioning in PTGX was balanced in Q2 2018: 17 funds opened new positions, 17 closed out, 27 added to existing stakes and 22 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $11.3M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $9.31M sold.
- 69 institutional investors held Protagonist Therapeutics (PTGX) as of Q2 2018, down from 70 in Q1 2018.
- Funds reported $93.6M of Protagonist Therapeutics stock for Q2 2018, down 8.7% quarter-over-quarter.
- 17 funds opened new Protagonist Therapeutics positions in Q2 2018 and 17 closed out, a net change of 0 holders.
- The largest Protagonist Therapeutics buyer in Q2 2018 was Great Point Partners, an estimated $11.3M added.
- The largest Protagonist Therapeutics seller in Q2 2018 was EcoR1 Capital, an estimated $9.31M sold.
Based on aggregated 13F filings for Q2 2018.